Alzheimer's Pathology Detection Made Simple

The recent emergence of promising new drug candidates for Alzheimer’s disease has highlighted an urgent need to facilitate the diagnosis of the disease in its early stages. Biomarkers are playing an increasingly important role in the diagnostic journey, including p-Tau, which has been shown to be highly associated with amyloid pathology which is a hallmark of AD. Currently the most established biomarker-based approaches in the diagnosis of AD include PET imaging and lumbar puncture, both of which are invasive, expensive, and may not be widely accessible. Download our whitepaper to learn more about the Lucent AD blood test.